SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

ACP-211

ACAD·ACADIA PHARMACEUTICALS INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
If Phase 2 succeeds, Phase 3 trials would follow, meaning potential FDA approval is likely several years away (probably 2029 or later under an optimistic scenario).
Why 3/10
The next hard catalyst is the NORLIGHT Phase 2 topline readout, guided for the second half of 2027 (more than 6 months away). ACP-211 is an early-stage pipeline asset at a company with two approved, revenue-generating drugs (DAYBUE and NUPLAZID) and several other pipeline programs, so this single drug is not a major value driver for the stock.
Actionable Insight NEUTRAL

The next catalyst for ACP-211 is the NORLIGHT Phase 2 topline readout, guided for the second half of 2027 (roughly 8-13 months away). A positive efficacy and safety readout would validate the oral deuterated norketamine approach and open a large addressable market in MDD/TRD. A negative or equivocal result would likely end the program but would not threaten ACADIA's core value, which rests on its commercial-stage DAYBUE and NUPLAZID franchises.

Price Chart

Loading chart...

Executive Summary

ACP-211 is ACADIA Pharmaceuticals' Phase 2 oral, once-daily, deuterated form of R-norketamine being developed as a monotherapy for major depressive disorder (MDD), including treatment-resistant depression (TRD). It is an NMDA receptor antagonist designed to improve upon the ketamine class by enabling oral administration with a potentially longer half-life via deuteration. The NORLIGHT Phase 2 trial (NCT07284667) is currently recruiting at 26 US sites with primary completion estimated in August 2027. On the Q3 2026 earnings call (Nov 4, 2026), management guided for a Phase 2 topline readout in the second half of 2027. ACP-211 is one of several early-to-mid-stage pipeline assets at ACADIA, which generates substantial revenue from two approved drugs (DAYBUE for Rett syndrome and NUPLAZID for Parkinson's disease psychosis). The drug faces competition from Johnson & Johnson's approved Spravato (esketamine nasal spray) and other ketamine-class developers.

How It Works

ACP-211 is an oral pill that blocks the NMDA receptor, a protein on brain cells involved in mood regulation. It is a selectively deuterated (chemically modified to slow breakdown in the body) form of R-norketamine, which is a metabolite of ketamine. The deuteration is intended to extend the drug's half-life enough to make a convenient once-daily oral pill feasible, unlike Johnson & Johnson's Spravato, which requires in-clinic nasal spray administration.

Trial Status

The NORLIGHT trial (NCT07284667) is a double-blind, placebo-controlled, parallel-group Phase 2 study evaluating ACP-211 monotherapy in adults with MDD who have had an inadequate response to antidepressant treatment, including treatment-resistant depression. The trial is actively recruiting at 26 sites across the United States. Estimated enrollment is 153 participants. Primary completion is estimated in August 2027.

The Two-Sided Case

▲ Bull Case4
Oral administration is a major differentiator versus Spravato (esketamine nasal spray), which requires in-clinic supervision after each dose, potentially giving ACP-211 a large commercial advantage if approved.
Deuteration of R-norketamine is a scientifically rational approach to extend half-life and enable oral dosing in a drug class with proven antidepressant efficacy.
ACADIA has a strong commercial infrastructure from DAYBUE and NUPLAZID that could be leveraged for a depression launch, and the company generated $342M in Q3 2026 revenue to fund development without near-term dilution risk.
Analyst consensus on ACAD is bullish (20 of 27 analysts rate Buy or Strong Buy) with a mean price target of $30.53, implying ~44% upside from the current ~$21.24 price.
▼ Bear Case5
Ketamine-class drugs carry known safety concerns including dissociation, abuse potential, and bladder toxicity, which could limit ACP-211's commercial opportunity even if efficacy is shown.
The Phase 2 readout is not expected until H2 2027, leaving the stock without a near-term catalyst from this program for roughly a year.
ACP-211 is one of several pipeline programs at ACADIA and is not the company's primary value driver, so even a positive readout may have limited impact on the stock price.
Competition in the depression space is intense: Spravato is already approved, and multiple other companies are developing oral ketamine-like drugs.
UBS downgraded ACAD from Buy to Neutral in October 2026, and the stock trades near its 52-week low of $18.39, reflecting some investor skepticism about pipeline execution.

Upcoming Catalysts

  • NORLIGHT Phase 2 topline readout for ACP-211 in MDD/TRD expected in the second half of 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ACADIA PHARMACEUTICALS INC 8-K ACAD ·Originating report

Sources · 10

Hover a chip for the title
1 acadia.com2 acadia.com3 ir.acadia.com4 behavioralwire.com5 clinicaltrials.gov6 synapse.patsnap.com7 adisinsight.springer.com8 spzco.com9 stockanalysis.com10 biopharmadive.com